US$ 26.99
noom microdose glp-1 Med Noom Introduces GLP-1 Microdoses of
Description
Safety considerations and side effects No responsible discussion of peptide safety glosses over side effects

The combined treatment of sCT and liraglutide, especially when administered in a stepwise manner, produced greater body weight loss, reduced adiposity and decreased plasma leptin levels compared to individual monotherapies and vehicle in DIO rats

These side effects occur in approximately 10-40% of patients depending on the specific medication and dose, typically appearing during dose initiation or escalation

IDF DIABETES ATLAS